bullish
Venus Medtech (启明医疗) IPO: Valuation Still OK at the High End
578 Views26 Nov 2019 15:25
Venus Medtech launched book building today to raise up to USD 331 million to list in Hong Kong. The deal attracted five cornerstone investors who...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
- Peijia Medical (沛嘉医疗) Pre-IPO: Deserves Valuation Premium for the TAVR Late Comer28 Apr 2020
- Peijia Medical (沛嘉医疗) Pre-IPO: Reminiscence of Venus Medtech?18 Feb 2020
- Venus Medtech (启明医疗) IPO Trading: Allocation and Buy-Level09 Dec 2019
- Venus Medtech (启明医疗) IPO: Valuation Still OK at the High End26 Nov 2019
- Venus Medtech (启明医疗) Pre-IPO: Thoughts on Valuation11 Nov 2019
- Venus Medtech (启明医疗) IPO: Technical Comparison of VenusA-Valve and Peers11 Sep 2019
x